Support Critical Legislation for Detection and Treatment of Alzheimer's Disease

Your elected officials need to hear from you! Below is an opportunity to support critical legislation that could transform early detection and treatment of Alzheimer’s Disease.

Ask your legislator to support H.R. 6130/S. 3267 – The Alzheimer’s Screening and Prevention (ASAP) Act – bipartisan legislation that would give Medicare the authority to cover routine blood-based screening tests for dementia, ensuring patients don’t face unnecessary delays or barriers to early detection and treatment.

A blood biomarker test is a simple blood draw that can detect Alzheimer’s pathology years before symptoms appear, sometimes during a routine doctor’s visit. These tests can identify disease pathology and help clinicians recognize patients that need additional more invasive testing, such as PET scans or spinal taps.

Early detection is critical because Alzheimer’s treatments are most effective in the earliest stages of the disease. Early diagnosis gives patients more time to access new therapies, enroll in clinical trials, and make important decisions about their care and future while still cognitively able.

As many as half of the 7 million Americans living with Alzheimer’s remain undiagnosed. H.R. 6130/S. 3267 would help close this gap by ensuring Medicare coverage keeps pace with rapidly advancing diagnostic technology, giving patients and their families the time and information they need most.  

Dear [Lawmaker],

As your constituent, I am requesting your support for H.R. 6130/S. 3267, the Alzheimer's Screening and Prevention (ASAP) Act. This bipartisan legislation would modernize Medicare's preventive coverage to ensure patients don't face unnecessary delays or barriers to early detection and treatment of Alzheimer's disease.

The ASAP Act would give Medicare the authority to cover routine blood-based dementia screening tests and future FDA-approved and cleared test methods. Currently, Medicare can only cover preventive services specifically authorized by Congress or recommended by the U.S. Preventive Services Task Force, a process that can delay coverage for years after screening tests receive FDA approval.

Blood biomarker tests are a breakthrough in early detection. In Alzheimer’s Disease, these tests can detect pathology years before symptoms appear, sometimes during a routine doctor's visit. These tests can identify disease pathology and help clinicians recognize patients that need additional more invasive testing, such as PET scans or spinal taps.

Early detection of Alzheimer’s is critical because treatments are most effective in the earliest stages of the disease. Early diagnosis also gives patients more time to access new therapies, enroll in clinical trials, and make important decisions about their care and future while still cognitively able.

More than 7 million Americans are living with Alzheimer's today - a number projected to reach 13 million by 2050.[1] Yet as many as half of those currently living with Alzheimer's remain undiagnosed.[2] The ASAP Act would help close this gap by ensuring Medicare coverage keeps pace with rapidly advancing diagnostic technology.

Please support the ASAP Act to help the millions of Americans access the early detection and care they need.

[1] https://www.alz.org/alzheimers-dementia/facts-figures#:~:text=in%20each%20state-,Quick%20facts,living%20with%20Alzheimer's%20in%202025.

[2] https://www.alz.org/news/2025/house-introduces-bipartisan-legislation-asap-act-alzheimers-screening

Sincerely,
______

Prefix

First Name

Last Name

Phone

Address

Zip